Provided by Tiger Fintech (Singapore) Pte. Ltd.

Veracyte

36.08
+0.75002.12%
Post-market: 36.190.1100+0.30%18:12 EDT
Volume:623.72K
Turnover:22.48M
Market Cap:2.84B
PE:107.48
High:36.38
Open:35.19
Low:35.16
Close:35.33
52wk High:47.32
52wk Low:22.61
Shares:78.67M
Float Shares:78.23M
Volume Ratio:1.08
T/O Rate:0.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3357
EPS(LYR):0.3156
ROE:2.24%
ROA:1.98%
PB:2.32
PE(LYR):114.32

Loading ...

Veracyte Inc expected to post earnings of 13 cents a share - Earnings Preview

Reuters
·
3 hours ago

Is Veracyte’s Recent 9.8% Rally a Sign of More Value in 2025?

Simply Wall St.
·
Oct 26

Canaccord Genuity Initiates Coverage on Veracyte With Hold Rating, $40 Price Target

MT Newswires Live
·
Oct 20

Veracyte Initiated at Hold by Canaccord Genuity

Dow Jones
·
Oct 20

Veracyte initiated with a Hold at Canaccord

TIPRANKS
·
Oct 20

Veracyte (VCYT): Assessing Valuation After Recent Momentum and Share Price Rebound

Simply Wall St.
·
Oct 18

Veracyte Initiated at Buy by Freedom Capital Markets

Dow Jones
·
Oct 17

Veracyte (VCYT) Receives a New Rating from Freedom Capital Markets

TIPRANKS
·
Oct 17

Veracyte initiated with a Buy at Freedom Capital

TIPRANKS
·
Oct 17

Press Release: Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Dow Jones
·
Oct 16

Veracyte (VCYT): Assessing Valuation After BALANCE Trial Data and Analyst Upgrades Boost Investor Confidence

Simply Wall St.
·
Oct 11

Veracyte Inc. Chief Scientific & Medical Officer Phillip G. Febbo Reports Disposal of Common Shares

Reuters
·
Oct 08

Veracyte Inc. SVP, General Counsel Annie McGuire Reports Disposal of Common Shares

Reuters
·
Oct 04

Veracyte Inc. Director Robert S. Epstein Reports Disposal of Common Shares

Reuters
·
Oct 04

Veracyte announces results from BALANCE trial of PAM50

TIPRANKS
·
Sep 29

Veracyte Announces Landmark Clinical Trial Results: PAM50 Biomarker Predicts Hormone Therapy Benefit in Recurrent Prostate Cancer

Reuters
·
Sep 29

Veracyte Announces That Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men With Recurrent Prostate Cancer

THOMSON REUTERS
·
Sep 29

Veracyte to Present First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Recurrent Prostate Cancer at ASTRO 2025

Reuters
·
Sep 24

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men With Recurrent Prostate Cancer Will Be Presented at Astro 2025

THOMSON REUTERS
·
Sep 24

Veracyte to Present Over 10 Afirma-Focused Studies at 2025 American Thyroid Association Annual Meeting

Reuters
·
Sep 09